Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Tipranavir (Aptivus; Boehringer Ingelheim) was given accelerated approval by the FDA for the treatment of HIV-1 infection in combination with other antiretroviral agents in June 2005. It is the first in a new class of non-peptidic HIV-1 protease inhibitors, and is active against HIV-1 strains that are resistant to other protease inhibitors.